Interaction between sarcopenia and nonalcoholic fatty liver disease

키워드

참고문헌 (119)

1. Loomba R, "The global NAFLD epidemic", Nat Rev Gastroenterol Hepatol, 10, pp.686~690 (2013)
2. Cruz-Jentoft AJ, "Sarcopenia : revised European consensus on definition and diagnosis", Age Ageing, 48, pp.16~31 (2019)
3. Koo BK, "Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis", J Hepatol, 66, pp.123~131 (2017)
4. Hong HC, "Relationship between sarcopenia and nonalcoholic fatty liver disease : the Korean Sarcopenic Obesity Study", Hepatology, 59, pp.1772~1778 (2014)
5. Issa D, "Presence of sarcopenia(muscle wasting)in patients with nonalcoholic steatohepatitis", Hepatology, 60, pp.428~429 (2014)
6. Lee YH, "Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance : nationwide surveys(KNHANES 2008-2011)", J Hepatol, 63, pp.486~493 (2015)
7. Lee YH, "Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease : nationwide surveys(KNHANES 2008-2011)", Hepatology, 63, pp.776~786 (2016)
8. Kim HY, "Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults : the Fifth Korea National Health and Nutrition Examination Survey", Hepatobiliary Pancreat Dis Int, 15, pp.39~47 (2016)
9. Petta S, "Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 45, pp.510~518 (2017)
10. Kim G, "Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease : a 7-year longitudinal study", Hepatology, 68, pp.1755~1768 (2018)
11. Min Jung Lee, "Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study", Gut and Liver, 13(1), pp.67~76 (2019), 거트앤리버 소화기연관학회협의회[DOI]
12. Zhai Y, "The relationship between NAFLD and sarcopenia in elderly patients", Can J Gastroenterol Hepatol, 2018, pp.5016091~ (2018)
13. Wijarnpreecha K, "Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA", Eur J Gastroenterol Hepatol, 31, pp.1121~1128 (2019)
14. Kang MK, "Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 34, pp.1633~1640 (2019)
15. Peng TC, "Nonalcoholic fatty liver disease and sarcopenia in a Western population(NHANES III) : the importance of sarcopenia definition", Clin Nutr, 38, pp.422~428 (2019)
16. Roh E, "Impact of non-alcoholic fatty liver disease on the risk of sarcopenia : a nationwide multicenter prospective study", Hepatol Int, 16, pp.545~554 (2022)
17. Kalyani RR, "Age-related and diseaserelated muscle loss : the effect of diabetes, obesity, and other diseases", Lancet Diabetes Endocrinol, 2, pp.819~829 (2014)
18. Wong E, "Diabetes and risk of physical disability in adults : a systematic review and meta-analysis", Lancet Diabetes Endocrinol, 1, pp.106~114 (2013)
19. Zhang H, "Association between sarcopenia and metabolic syndrome in middle-aged and older non-obese adults : a systematic review and metaanalysis", Nutrients, 10, pp.364~ (2018)
20. Hsu CS, "Sarcopenia and chronic liver diseases", Expert Rev Gastroenterol Hepatol, 12, pp.1229~1244 (2018)
21. Bauer J, "Sarcopenia : a time for action. An SCWD position paper", J Cachexia Sarcopenia Muscle, 10, pp.956~961 (2019)
22. Bhanji RA, "Sarcopenia in hiding : the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis", Hepatology, 66, pp.2055~2065 (2017)
23. DeFronzo RA, "Skeletal muscle insulin resistance is the primary defect in type 2 diabetes", Diabetes Care, 32(Suppl 2), pp.S157~S163 (2009)
24. Reaven GM, "Banting lecture 1988. Role of insulin resistance in human disease", Diabetes, 37, pp.1595~1607 (1988)
25. Postic C, "Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance : lessons from genetically engineered mice", J Clin Invest, 118, pp.829~838 (2008)
26. Martín-Domínguez V, "Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease", Rev Esp Enferm Dig, 105, pp.409~420 (2013)
27. Guillet C, "Insulin resistance: a contributing factor to age-related muscle mass loss?", Diabetes Metab, 31(Spec No 2), pp.5S20~5S26 (2005)
28. Bonaldo P, "Cellular and molecular mechanisms of muscle atrophy", Dis Model Mech, 6, pp.25~39 (2013)
29. Fujita S, "Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults : evidence of a true age-related insulin resistance of muscle protein metabolism", Diabetologia, 52, pp.1889~1898 (2009)
30. Fujita S, "Aerobic exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt", mammalian target of rapamycin signaling, 2007, pp.56, 1615~1622
31. Turcotte LP, "Skeletal muscle insulin resistance : roles of fatty acid metabolism and exercise", Phys Ther, 88, pp.1279~1296 (2008)
32. Kim TN, "Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes : the Korean Sarcopenic Obesity Study(KSOS)", Diabetes Care, 33, pp.1497~1499 (2010)
33. Srikanthan P, "Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia : findings from the National Health and Nutrition Examination Survey III", PLoS One, 5, pp.e10805~ (2010)
34. Montano-Loza AJ, "Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis", J Cachexia Sarcopenia Muscle, 7, pp.126~135 (2016)
35. Stephen WC, "Sarcopenic-obesity and cardiovascular disease risk in the elderly", J Nutr Health Aging, 13, pp.460~466 (2009)
36. Beyer I, "Chronic low-grade inflammation and age-related sarcopenia", Curr Opin Clin Nutr Metab Care, 15, pp.12~22 (2012)
37. Ji Won Han, "Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis", Clinical and Molecular Hepatology, 28(2), pp.219~231 (2022), 대한간학회[DOI]
38. Hui JM, "Beyond insulin resistance in NASH : TNF-alpha or adiponectin?", Hepatology, 40, pp.46~54 (2004)
39. Wree A, "Obesity affects the liver-the link between adipocytes and hepatocytes", Digestion, 83, pp.124~133 (2011)
40. Takumi Kawaguchi, "Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis", Clinical and Molecular Hepatology, 28(2), pp.177~180 (2022), 대한간학회[DOI]
41. Tilg H, "Insulin resistance, inflammation, and non-alcoholic fatty liver disease", Trends Endocrinol Metab, 19, pp.371~379 (2008)
42. Cesari M, "ACE-inhibition and physical function : results from the Trial of AngiotensinConverting Enzyme Inhibition and Novel Cardiovascular Risk Factors(TRAIN)study", J Am Med Dir Assoc, 11, pp.26~32 (2010)
43. Eliades M, "Meta-analysis : vitamin D and non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 38, pp.246~254 (2013)
44. Pang Q, "Sarcopenia and nonalcoholic fatty liver disease : new evidence for low vitamin D status contributing to the link", Hepatology, 63, pp.675~ (2016)
45. Ceglia L, "Vitamin D and skeletal muscle tissue and function", Mol Aspects Med, 29, pp.407~414 (2008)
46. Bouillon R, "Vitamin D and health : perspectives from mice and man", J Bone Miner Res, 23, pp.974~979 (2008)
47. Garcia LA, "1, 25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells", Endocrinology, 152, pp.2976~2986 (2011)
48. Han S, "Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes", Drug Metab Dispos, 37, pp.469~478 (2009)
49. Girgis CM, "The roles of vitamin D in skeletal muscle : form, function, and metabolism", Endocr Rev, 34, pp.33~83 (2013)
50. Barchetta I, "Strong association between non alcoholic fatty liver disease(NAFLD)and low 25(OH)vitamin D levels in an adult population with normal serum liver enzymes", BMC Med, 9, pp.85~ (2011)
51. Visser M, "Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass(sarcopenia) : the Longitudinal Aging Study Amsterdam", J Clin Endocrinol Metab, 88, pp.5766~5772 (2003)
52. Tanaka K, "Active vitamin D possesses beneficial effects on the interaction between muscle and bone", Biochem Biophys Res Commun, 450, pp.482~487 (2014)
53. Yin Y, "Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism", Eur J Clin Invest, 42, pp.1189~1196 (2012)
54. Dunlop TW, "The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha, 25-dihydroxyvitamin D3 and its nuclear receptor", J Mol Biol, 349, pp.248~260 (2005)
55. Roth CL, "Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation", Hepatology, 55, pp.1103~1111 (2012)
56. Nelson JE, "Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease : possible role for MAPK and NF-κB?", Am J Gastroenterol, 111, pp.852~863 (2016)
57. Patel YA, "Vitamin D is not associated with severity in NAFLD : results of a paired clinical and gene expression profile analysis", Am J Gastroenterol, 111, pp.1591~1598 (2016)
58. Pedersen BK, "Muscles and their myokines", J Exp Biol, 214(Pt 2), pp.337~346 (2011)
59. Hartwig S, "Secretome profiling of primary human skeletal muscle cells", Biochim Biophys Acta, 1844, pp.1011~1017 (2014)
60. Raschke S, "Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells", PLoS One, 8, pp.e62008~ (2013)
61. Carson BP, "The potential role of contraction-induced myokines in the regulation of metabolic function for the prevention and treatment of type 2 diabetes", Front Endocrinol(Lausanne), 8, pp.97~ (2017)
62. Koo BK, "Growth differentiation factor 15 predicts advanced fibrosis in biopsyproven non-alcoholic fatty liver disease", Liver Int, 38, pp.695~705 (2018)
63. Sooyeon Oh, "Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma", Clinical and Molecular Hepatology, 26(4), pp.476~479 (2020), 대한간학회
64. Ji S, "Myostatin expression in porcine tissues : tissue specificity and developmental and postnatal regulation", Am J Physiol, 275, pp.R1265~R1273 (1998)
65. McPherron AC, "Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member", Nature, 387, pp.83~90 (1997)
66. Lee SJ, "Myostatin and the control of skeletal muscle mass", Curr Opin Genet Dev, 9, pp.604~607 (1999)
67. Rebbapragada A, "Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis", Mol Cell Biol, 23, pp.7230~7242 (2003)
68. Artaza JN, "Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1", 2)mesenchymal multipotent cells, 2005, pp.146, 3547~3557
69. Han HQ, "Myostatin", activin pathway antagonism : molecular basis and therapeutic potential, 2013, pp.45, 2333~2347
70. Suzuki ST, "Enhanced muscle by myostatin propeptide increases adipose tissue adiponectin, PPAR-alpha, and PPAR-gamma expressions", Biochem Biophys Res Commun, 369, pp.767~773 (2008)
71. Dasarathy S, "Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease?", Hepatology, 60, pp.22~25 (2014)
72. Wilkes JJ, "Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance", Diabetes, 58, pp.1133~1143 (2009)
73. Zhang C, "Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway", Diabetologia, 54, pp.1491~1501 (2011)
74. Pistilli EE, "Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy", Am J Pathol, 178, pp.1287~1297 (2011)
75. Amthor H, "Interference with myostatin", ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy, 2012, pp.12, 245~259
76. Delogu W, "Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation", Dig Liver Dis, 51, pp.1400~1408 (2019)
77. Zhang HJ, "Irisin is inversely associated with intrahepatic triglyceride contents in obese adults", J Hepatol, 59, pp.557~562 (2013)
78. Xu J, "Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in dietinduced obese mice", Diabetes, 58, pp.250~259 (2009)
79. Lee HJ, "Irisin, a novel myokine, regulates glucose uptake in skeletal muscle cells via AMPK", Mol Endocrinol, 29, pp.873~881 (2015)
80. Moreno-Navarrete JM, "Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance", J Clin Endocrinol Metab, 98, pp.E769~E778 (2013)
81. Pedersen BK, "Muscle as an endocrine organ : focus on muscle-derived interleukin-6", Physiol Rev, 88, pp.1379~1406 (2008)
82. Pedersen BK, "Searching for the exercise factor : is IL-6 a candidate?", J Muscle Res Cell Motil, 24, pp.113~119 (2003)
83. Helge JW, "The effect of graded exercise on IL-6 release and glucose uptake in human skeletal muscle", J Physiol, 546(Pt 1), pp.299~305 (2003)
84. Steensberg A, "Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6", J Physiol, 529(Pt 1), pp.237~242 (2000)
85. Ellingsgaard H, "Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells", Nat Med, 17, pp.1481~1489 (2011)
86. Paula FM, "Exercise increases pancreatic β-cell viability in a model of type 1 diabetes through IL-6 signaling", FASEB J, 29, pp.1805~1816 (2015)
87. Al-Khalili L, "Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle", Mol Endocrinol, 20, pp.3364~3375 (2006)
88. Carey AL, "Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase", Diabetes, 55, pp.2688~2697 (2006)
89. Kanghyug Choi, "The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma", Clinical and Molecular Hepatology, 26(4), pp.492~505 (2020), 대한간학회[DOI]
90. Wieckowska A, "Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis", Am J Gastroenterol, 103, pp.1372~1379 (2008)
91. Biolo G, "Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases : from sarcopenic obesity to cachexia", Clin Nutr, 33, pp.737~748 (2014)
92. Lang T, "Sarcopenia : etiology, clinical consequences, intervention, and assessment", Osteoporos Int, 21, pp.543~559 (2010)
93. Steffl M, "Relationship between sarcopenia and physical activity in older people : a systematic review and meta-analysis", Clin Interv Aging, 12, pp.835~845 (2017)
94. Johnson NA, "Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss", Hepatology, 50, pp.1105~1112 (2009)
95. Kob R, "Sarcopenic obesity : molecular clues to a better understanding of its pathogenesis?", Biogerontology, 16, pp.15~29 (2015)
96. Yamauchi T, "Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase", Nat Med, 8, pp.1288~1295 (2002)
97. Tilg H, "Nonalcoholic fatty liver disease : cytokine-adipokine interplay and regulation of insulin resistance", Gastroenterology, 131, pp.934~945 (2006)
98. Ryall JG, "Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology 2008;9 : 213-228. 99 Egerman MA, Glass DJ. Signaling pathways controlling skeletal muscle mass", Crit Rev Biochem Mol Biol, 49, pp.59~68 (2014)
99. Berryman DE, "The GH", IGF-1axis in obesity : pathophysiology and therapeutic considerations, 2013, pp.9, 346~356
100. Cabrera D, "Diet-induced nonalcoholic fatty liver disease is associated with sarcopenia and decreased serum insulin-like growth factor-1", Dig Dis Sci, 61, pp.3190~3198 (2016)
101. Pan X, "Sarcopenia contributes to the progression of nonalcoholic fatty liver diseaserelated fibrosis : a meta-analysis", Dig Dis, 36, pp.427~436 (2018)
102. Yu R, "Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease : a meta-analysis", BMC Gastroenterol, 18, pp.51~ (2018)
103. Hsieh YC, "Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease", Liver Int, 41, pp.494~504 (2021)
104. Golabi P, "Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease", JHEP Rep, 2, pp.100171~ (2020)
105. Moon JH, "Non-alcoholic fatty liver disease and sarcopenia additively increase mortality : a Korean nationwide survey", J Cachexia Sarcopenia Muscle, 12, pp.964~972 (2021)
106. Sinn DH, "Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass : a longitudinal cohort study", Hepatology, 76, pp.1746~1754 (2022)
107. Nachit M, "Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. J Cachexia Sarcopenia Muscle 2021;12 : 144-158. 109 Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation", Liver Transpl, 20, pp.640~648 (2014)
108. Nachit M, "Muscle fat content is strongly associated with NASH : a longitudinal study in patients with morbid obesity", J Hepatol, 75, pp.292~301 (2021)
109. Hsieh YC, "Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression", Clin Gastroenterol Hepatol (2022)[DOI]
110. Nachit M, "A dynamic association between myosteatosis and liver stiffness : results from a prospective interventional study in obese patients", JHEP Rep, 3, pp.100323~ (2021)
111. Gan D, "Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease", Clin Nutr, 39, pp.1124~1130 (2020)
112. Kitajima Y, "Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle", J Gastroenterol Hepatol, 28, pp.1507~1514 (2013)
113. Nachit M, "Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms!", Clin Sci (Lond), 133, pp.465~481 (2019)
114. Tanaka M, "Relationship between nonalcoholic fatty liver disease and muscle quality as well as quantity evaluated by computed tomography", Liver Int, 40, pp.120~130 (2020)
115. Kang S, "Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease : a Korean nationwide survey", J Cachexia Sarcopenia Muscle, 11, pp.1232~1241 (2020)
116. Ebadi M, "Clinical relevance of skeletal muscle abnormalities in patients with cirrhosis", Dig Liver Dis, 51, pp.1493~1499 (2019)
117. Bhanji RA, "Differing impact of sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease", Liver Transpl, 25, pp.14~24 (2019)
118. Tae Hyung Kim, "Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis", Clinical and Molecular Hepatology, 28(4), pp.876~889 (2022), 대한간학회
119. Do Seon Song, "Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”", Clinical and Molecular Hepatology, 29(1), pp.165~167 (2023), 대한간학회